Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : BEAT UP, NEGLECTED, UNKNOWN OR UNLOVED MICROS. -- Ignore unavailable to you. Want to Upgrade?

To: rrufff who wrote (616)	6/26/2007 2:30:40 PM
From: rrufff	Read Replies (1) \| Respond to of 624

AEMD .70 + .03 see prior posts. Aethlon Medical Signs Cooperative Research and Development Agreement with The U.S. Army Medical Research Institute of Infectious DiseasesLast update: 6/26/2007 8:30:35 AMSAN DIEGO, Jun 26, 2007 (BUSINESS WIRE) -- Aethlon Medical, Inc. (AEMD), announced today that it has executed a Cooperative Research and Development Agreement (CRADA) with The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The focus of the agreement is to explore the therapeutic efficacy of the Aethlon Hemopurifier(R) against viral hemorrhagic fever (VHF) targets, including, but not limited to Ebola Virus, Marburg Virus, Lassa Virus, and Machupo Virus. (see rest of pr and disclaimer)